Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 55Recruiting 20Unknown 12Active not recruiting 8Terminated 7Withdrawn 4Enrolling by invitation 3Not yet recruiting 2Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Tuberous Sclerosis × Clear all
NCT07575347 2026-05-08

PERIO-RA-RE

Institutul Clinic Fundeni

Not yet recruiting
100 enrolled

Fabry Disease, Lupus Erythematosus, Systemic, Nephritis, Hereditary, Periodontal Diseases, Periodontitis, Tuberous Sclerosis, Renal Insufficiency, Chronic

NCT07287202 2025-12-23

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Sovargen

Phase 1/2 Not yet recruiting
15 enrolled

Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly

Data powered by HemOnc (CC BY 4.0) Colophon âš¡